Cargando…

Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study

Coronavirus disease 2019 (COVID-19) has rapidly expanded worldwide. Currently, there are no biomarkers to predict respiratory worsening in patients with mild to moderate COVID-19 pneumonia. Small studies explored the use of Krebs von de Lungen-6 circulating serum levels (sKL-6) as a prognostic bioma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castellví, Ivan, Castillo, Diego, Corominas, Hèctor, Mariscal, Anaís, Orozco, Sandra, Benito, Natividad, Pomar, Virginia, Baucells, Andrés, Mur, Isabel, de la Rosa-Carrillo, David, Lobo, David, Millan, Ana Milena, Hernández de Sosa, Nerea, Filella, David, Matas, Laia, Martínez-Martínez, Laura, Juarez, Cándido, Casademont, Jordi, Domingo, Pere
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393380/ https://www.ncbi.nlm.nih.gov/pubmed/36004366 http://dx.doi.org/10.3389/fmed.2022.973918

Ejemplares similares

Krebs von den Lungen‐6 levels in untreated idiopathic pulmonary fibrosis
por: Jiang, Dingyuan, et al.
Publicado: (2022)

Krebs von den Lungen 6 decreased in the serum and muscle of GNE myopathy patients
por: Kurashige, Takashi, et al.
Publicado: (2020)

Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis
por: Mostafa, Amira Ismail, et al.
Publicado: (2021)

Effects of molecular structural variants on serum Krebs von den Lungen-6 levels in sarcoidosis
por: Shigemura, Masahiko, et al.
Publicado: (2012)

Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019
por: Peng, Ding-Hui, et al.
Publicado: (2021)

Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
por: Xue, Mingshan, et al.
Publicado: (2021)

Exploring the Role of Krebs von den Lungen-6 in Severe to Critical COVID-19 Patients
por: D’Agnano, Vito, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6: Promising biomarker to differentiate CPFE from IPF
por: Demirdöğen, Ezgi, et al.
Publicado: (2022)

Krebs von den Lungen-6 (KL-6) in cerebrospinal fluid from neurosarcoidosis patients
por: Bocci, Silvia, et al.
Publicado: (2023)

Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease
por: Ko, Ui Won, et al.
Publicado: (2020)

Clinical relevance of serum Krebs von den Lungen-6 levels in patients with coronavirus disease 2019
por: Chen, Hao, et al.
Publicado: (2021)

Distribution of Presepsin, Krebs von den Lungen 6, and Surfactant Protein A in Umbilical Cord Blood
por: Nam, Minjeong, et al.
Publicado: (2022)

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort()
por: Corominas, Hèctor, et al.
Publicado: (2021)

Krebs von den Lungen-6 (KL-6) Levels in Post-COVID Follow-Up: Differences According to the Severity of COVID-19
por: Carpio, Carlos, et al.
Publicado: (2023)

Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019
por: Yamaya, Takafumi, et al.
Publicado: (2021)

Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis
por: Chung, Chiwook, et al.
Publicado: (2022)

Krebs von den Lungen 6 (KL-6) levels in COVID-19 ICU patients are associated with mortality
por: Scarpati, Giuliana, et al.
Publicado: (2022)

Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19
por: Benito, Natividad, et al.
Publicado: (2020)

Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases
por: Cho, Eun-Jung, et al.
Publicado: (2019)

The Prognostic Value of Krebs von den Lungen-6 and Surfactant Protein-A Levels in the Patients with Interstitial Lung Disease
por: Zheng, Peiyan, et al.
Publicado: (2021)

Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis
por: He, Jie, et al.
Publicado: (2022)

1357. Initial and Peak Serum Levels of Krebs von den Lungen-6 for Prediction of Prognosis in Patients with COVID-19
por: Kim, Geonui, et al.
Publicado: (2023)

The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
por: Domingo, Pere, et al.
Publicado: (2020)

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
por: Corominas, Hèctor, et al.
Publicado: (2021)

Novel Usefulness of Krebs von den Lungen 6 (KL-6) with Hemoglobin and Lactate Dehydrogenase for Assessing Bone Marrow Fibrosis
por: Nam, Minjeong, et al.
Publicado: (2022)

Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease
por: Ma, Hua, et al.
Publicado: (2020)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis
por: Witarto, Andro Pramana, et al.
Publicado: (2021)

Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients
por: Xue, Mingshan, et al.
Publicado: (2021)

Impact of diabetes and Krebs von den Lungen‐6 on coronavirus disease 2019 severity: A single‐center study from Japan
por: Yakushiji, Yosuke, et al.
Publicado: (2022)

Circulatory Serum Krebs von Den Lungen-6 and Surfactant Protein-D Concentrations Predict Interstitial Lung Disease Progression and Mortality
por: Rai, Meghna, et al.
Publicado: (2023)

Not all COVID-19 pandemic waves are alike
por: Domingo, Pere, et al.
Publicado: (2021)

Krebs von den Lungen 6 (KL-6) as a marker for disease severity and persistent radiological abnormalities following COVID-19 infection at 12 weeks
por: Arnold, David T., et al.
Publicado: (2021)

Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses
por: Naderi, Nadereh, et al.
Publicado: (2022)

Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19: A Systematic Review, Meta-Analysis, and Trial Sequence Analysis
por: Shrestha, Abhigan Babu, et al.
Publicado: (2023)

Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis
por: Matuszewski, Michal, et al.
Publicado: (2022)

Evaluation of the clinical performance of the HISCL‐5000 analyzer in the detection of Krebs von den Lungen‐6 antigen and its diagnostic value in interstitial lung disease
por: Wang, Jingxian, et al.
Publicado: (2019)

Histologic Chorioamnionitis, Amniotic Fluid Interleukin 6, Krebs von den Lungen 6, and Transforming Growth Factor β(1) for the Development of Neonatal Bronchopulmonary Dysplasia
por: Matsumura, Hisako, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5dvvskji7c8nq8n6kqebctdf0n